A phase I trial combining decitabine/dendritic cell vaccine targeting MAGE-A1, MAGE-A3 and NY-ESO-1 for children with relapsed or therapy-refractory neuroblastoma and sarcoma
Crossref DOI link: https://doi.org/10.1007/s00262-015-1731-3
Published Online: 2015-06-24
Published Print: 2015-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Krishnadas, Deepa K.
Shusterman, Suzanne
Bai, Fanqi
Diller, Lisa
Sullivan, Janice E.
Cheerva, Alexandra C.
George, Rani E.
Lucas, Kenneth G.
Text and Data Mining valid from 2015-06-24
Version of Record valid from 2015-06-24
Article History
Received: 7 October 2014
Accepted: 2 June 2015
First Online: 24 June 2015